The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: A retrospective analysis of the Gruppo Italiano Trapianto di Midollo Osseo

Leukemia

Volumn 27, Issue 10, 2013, Pages 2086-2091

  Todisco, E ^a   Ciceri, F ^b   Oldani, E ^c   Boschini, C ^c   Mico C ^c   Vanlint, M T ^d   Donnini, I ^e   Patriarca, F ^f   Alessandrino, P E ^g   Bonifazi, F ^h   Arcese, W ⁱ   Barberi, W ^j   Marenco, P ^k   Terruzzi, E ^l   Cortelazzo, S ^m   Santarone, S ⁿ   Proia, A ^o   Corradini, P ^p   Tagliaferri, E ^q   Falcioni, S ^r   Irrera, G ^s   Dallanegra, L ^t   Castagna, L ^a   Santoro, A ^a   Camboni, A ^u   Sacchi, N ^v   Bosi, A ^e   Bacigalupo, A ^d   Rambaldi, A ^c   more..

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l SAN GERARDO HOSPITAL   (Italy)

^m Ospedale Regionale   (Italy)

ⁿ SPIRITO SANTO HOSPITAL   (Italy)

^o SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^p UNIVERSITY OF MILAN   (Italy)

^q FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^r Division of Hematology   (Italy)

^s Divisione di Ematologia   (Italy)

^t Ospedale Civile   (Italy)

^u Segreteria Nazionale GITMO   (Italy)

^v Italian Bone Marrow Donor Registry   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CYTOMEGALOVIRUS; EVENT FREE SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; KARNOFSKY PERFORMANCE STATUS; LETTER; LEUKEMIA RELAPSE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SCORING SYSTEM; SURVIVAL RATE; T CELL DEPLETION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84885622365     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.208     Document Type: Letter

References (13)

1. Greinix HT, Reiter E, Keil F, Fischer G, Lechner K, Dieckmann K et al. Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors. Bone Marrow Transplant 1998; 21: 673-678.
2. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157-1163.
3. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108-114.
4. Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932-936.
5. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011; 25: 808-813.
6. Duval M, Klein JP, He W, Cahn J-Y, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730-3738.
7. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
8. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
9. Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M et al. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia 2012; 26: 1779-1785.
10. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19: 916-920.
11. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
12. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013; 48(Suppl 1): S1-S37.
13. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol 2007; 20: 29-37.